ERBB2 and metastatic neoplasm: The study population included 494 (88.7%) patients with HR-positive disease and 63 (11.3%) with HR-negative disease, 58% of patients had HER2 IHC 1+ and 42% IHC 2+; the liver was the most common site of metastatic disease, followed by lungs [12].